foscarnet has been researched along with Neutropenia in 8 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 9.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "To determine if ganciclovir given three times per week post-transplant is tolerable and effective for prevention of cytomegalovirus (CMV) infection in recipients of T cell-depleted marrow from related or unrelated donors, we have used ganciclovir 2." | 7.69 | Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. ( Andersson, B; Deisseroth, AB; Giralt, S; Goodrich, J; Ippoliti, C; Luna, M; Mehra, R; Panina, A; Przepiorka, D; van Besien, K, 1994) |
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 5.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "To determine if ganciclovir given three times per week post-transplant is tolerable and effective for prevention of cytomegalovirus (CMV) infection in recipients of T cell-depleted marrow from related or unrelated donors, we have used ganciclovir 2." | 3.69 | Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. ( Andersson, B; Deisseroth, AB; Giralt, S; Goodrich, J; Ippoliti, C; Luna, M; Mehra, R; Panina, A; Przepiorka, D; van Besien, K, 1994) |
| "Advances in ganciclovir and foscarnet therapies for treating cytomegalovirus retinitis, including ocular implants and injections, alternating use of foscarnet and ganciclovir, oral ganciclovir use, cidofovir treatment, and injecting either ganciclovir or foscarnet directly into affected eyes, are discussed." | 3.69 | Advances in treatment for cytomegalovirus retinitis. ( Bowers, M, 1995) |
| "During study treatment, severe neutropenia (< 0." | 2.70 | Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. ( Cordonnier, C; Einsele, H; Engelhard, D; Finke, J; Lee, J; Link, H; Ljungman, P; Reusser, P; Rovira, M; Volin, L, 2002) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ridha, E | 1 |
| Cookson, H | 1 |
| Devitt, E | 1 |
| Nelson, M | 1 |
| Nash, PJ | 1 |
| Avery, RK | 1 |
| Tang, WH | 1 |
| Starling, RC | 1 |
| Taege, AJ | 1 |
| Yamani, MH | 1 |
| Przepiorka, D | 1 |
| Ippoliti, C | 1 |
| Panina, A | 1 |
| Goodrich, J | 1 |
| Giralt, S | 1 |
| van Besien, K | 1 |
| Mehra, R | 1 |
| Deisseroth, AB | 1 |
| Andersson, B | 1 |
| Luna, M | 1 |
| Iino, T | 1 |
| Gondo, H | 1 |
| Ohno, Y | 1 |
| Minagawa, H | 1 |
| Iwasaki, H | 1 |
| Maruyama, T | 1 |
| Nakashima, H | 1 |
| Niho, Y | 1 |
| Bowers, M | 1 |
| Reusser, P | 1 |
| Einsele, H | 1 |
| Lee, J | 1 |
| Volin, L | 1 |
| Rovira, M | 1 |
| Engelhard, D | 1 |
| Finke, J | 1 |
| Cordonnier, C | 1 |
| Link, H | 1 |
| Ljungman, P | 1 |
| Peters, BS | 1 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 1 |
| Harris, JR | 1 |
| Pinching, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant[NCT00386412] | Phase 2 | 132 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
2 trials available for foscarnet and Neutropenia
| Article | Year |
|---|---|
Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
Topics: Acute Kidney Injury; Adolescent; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retin | 1995 |
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Child; Cytomegalovirus Infections; Disease-Free Survival; Drug | 2002 |
6 other studies available for foscarnet and Neutropenia
| Article | Year |
|---|---|
Febrile neutropenia in a HIV positive individual post-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytomegalovirus | 2010 |
Encephalitis owing to human herpesvirus-6 after cardiac transplant.
Topics: Adult; Antiviral Agents; Cytomegalovirus; DNA, Viral; Encephalitis; Foscarnet; Heart Transplantation | 2004 |
Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; Drug Ad | 1994 |
Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation.
Topics: Acyclovir; Adult; Antiviral Agents; Bone Marrow Transplantation; Drug Resistance, Microbial; Foscarn | 1996 |
Advances in treatment for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antiviral Agents; Cytomegalovirus Retiniti | 1995 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |